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Innate immune factors may restrict hematopoietic
stem cell (HSC) genetic engineering and contribute
to broad individual variability in gene therapy out-
comes. Here, we show that HSCs harbor an early,
constitutively active innate immune block to lentiviral
transduction that can be efficiently overcome by
cyclosporine H (CsH). CsH potently enhances gene
transfer and editing in human long-term repopulating
HSCs by inhibiting interferon-induced transmem-
brane protein 3 (IFITM3), which potently restricts
VSV glycoprotein-mediated vector entry. Impor-
tantly, individual variability in endogenous IFITM3
levels correlatedwith permissiveness of HSCs to len-
tiviral transduction, suggesting that CsH treatment
will be useful for improving ex vivo gene therapy
and standardizing HSC transduction across patients.
Overall, our work unravels the involvement of innate
pathogen recognition molecules in immune blocks
to gene correction in primary human HSCs and high-
lights how these roadblocks can be overcome to
develop innovative cell and gene therapies.
INTRODUCTION
The limited efficiency of genemanipulation in human hematopoi-
etic stem and progenitor cells (HSPC) remains a major hurdle for
effective clinical application of genetic therapies for a wide range
of disorders. Indeed, high vector doses and prolonged ex vivo
culture are still required for effective gene transfer, even with
the most established lentiviral vector (LV)-based delivery plat-
forms. Various transduction enhancers have been identified
(Heffner et al., 2018; Petrillo et al., 2015;Wang et al., 2014; Zonari
et al., 2017), which impact the LV life cycle at different stages
from vector entry to integration. This highlights the existence of
multiple barriers to gene transfer in HSPC.Cell Stem Cell 23, 1–13, De
This is an open access article under the CC BY-NWe previously observed that cyclosporine A (CsA) enhances
transduction in HSPC, contrasting with its well-known inhibitory
activity against lentiviruses (Petrillo et al., 2015; Rasaiyaah et al.,
2013). In differentiated cells, CsA inhibits lentiviral infection
through interfering with the interaction of the HIV-1 capsid with
the host cofactor cyclophilin A (CypA), which is important for
optimal DNA synthesis, capsid uncoating and nuclear import of
the viral pre-integration complex (PIC) (Hilditch and Towers,
2014). It has been unclear how CsA enhances LV transduction
in HSPC.
There is increasing evidence that HSPC are responsive to
type-I interferon (IFN)-mediated innate immune signaling (Essers
et al., 2009; Haas et al., 2015; Hirche et al., 2017; Nagai et al.,
2006). Although we have demonstrated that LV transduction
does not trigger type I IFN signaling in HSPC (Piras et al.,
2017), it has recently been shown that stem cells constitutively
express genes that are typically IFN-inducible. This protects
HSPC from viral infections (Wu et al., 2018). Although many of
these antiviral host factors are known to potently restrict retro-
viral infections in mammalian cells (Towers and Noursadeghi,
2014), their potential impact on LV gene transfer in HSPC re-
mains poorly characterized (Kajaste-Rudnitski and Nal-
dini, 2015).
Here, we identify a potent steady-state restriction of LV-medi-
ated gene transfer in human HSPC. We demonstrate that this
barrier can be efficiently overcome by the non-immunosuppres-
sive cyclosporine H (CsH), leading to significantly enhanced
transduction and gene editing efficiencies in human HSPC.RESULTS
A CypA-Independent Cyclosporine Reveals an Early
Block to LV Transduction in HSPCs
The reduction of LV infection in differentiated cells by CsA is due
to inhibition of CypA recruitment to the incoming HIV-1 capsid
(CA) (Sokolskaja and Luban, 2006; Towers, 2007; Towers et al.,
2003). In agreementwith a cofactor role for CypAduring LV trans-
duction, depletion of CypA led to lower transduction of human
HSPC (Figures S1A–S1D). This implies that the capacity of CsAcember 6, 2018 ª 2018 The Author(s). Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that it will also interferewith this positive CypA-vector interaction.
Based on these results, and our previous observation that the
immunosuppressive arm of CsA is not involved in enhancing LV
transduction in HSPC (Petrillo et al., 2015), we tested a naturally
occurring cyclosporine, cyclosporine H (CsH), which does not
bind CypA and is not immunosuppressive (Figure S1E) (Jeffery,
1991). Remarkably, CsH was more potent than CsA at the
same 8mM dose and increased LV transduction up to 10-fold in
human cord blood (CB)-derived HSPC (Figure 1A). Higher doses
of CsH further increased transduction (Figure S1F) but were toxic
(Figures 1BandS1G). CsH improved transduction as early as 2 hr
post-exposure but optimal efficacy was achieved after overnight
(16 hr) exposure (Figures S1H and S1I). The enhancement was
lower if CsH was removed prior to transduction but could be
restored by blocking de novo protein synthesis during the 6 hr
of vector exposure (Figure S1J). Remarkably, CsH rendered
HSPC as permissive as the highly transducible 293T cell line (Fig-
ure 1C). Importantly, CsH was effective in the clinically relevant
human mobilized peripheral blood (mPB)-derived CD34+ cells,
in murine HSPC (Figures 1D and 1E) and in all CD34+ subpopula-
tions, including in the more primitive CD34+CD133+CD90+ frac-
tion (Figure 1F), without altering the subpopulation composition
nor the cell-cycle status (Figures 1G and 1H). Unlike CsA, no pro-
liferation delaywas observedwith CsH, in linewith CsH not being
immunosuppressive (Figure 1I). CsH was more potent and addi-
tive with transduction enhancers Rapamycin (Rapa) (Petrillo
et al., 2015;Wang et al., 2014) andPGE2 (Heffner et al., 2018; Zo-
nari et al., 2017) but not with CsA (Figures 1J–1L). CsH also
increased LV transduction in unstimulated HSPC (Figure 1M),
but did not alter transduction in primary human monocyte-
derived macrophages (MDM) (Figure S1K). This was irrespective
of SAMHD1-mediated LV restriction, which can be overcome
by incorporating the simian immunodeficiency virus macaque
(SIVmac) accessory protein Vpx into the LV particle (Bobadilla
et al., 2013). Conversely, we saw a statistically significant in-
crease in the percentage of transduced (GFP+) activated T cells
with CsH (Figure S1L). These data are in contrast with the inhibi-
tory effect of CsA that we and others have observed in this cell
type (Donahue et al., 2017; Lahaye et al., 2016; Petrillo et al.,
2015). This further underscores how the CypA-dependent CsA
inhibition of LV infection likely masks its enhancement of trans-
duction. Indeed, CsA increased transduction of the CypA-inde-
pendent P90A LV capsid mutant, which does not recruit CypA,
to similar extent as CsH in HSPC (Figure S1M). CsH also
increased transduction of the CPSF6-independent N74D capsid
mutant (Lee et al., 2010) (FigureS1N), ruling outCPSF6 in theCsH
enhancement mechanism. Of note, transduction by an SIVmac-
derived vector, which does not interact with human CypA (Luban
et al., 1993), was also increased by both cyclosporines in human
CD34+ cells (Figure S1O). To further dissect the step of the viral
life cycle affected by CsH, we measured viral DNA replication in-
termediates early after transduction.Consistentwith the increase
in infection, CsH led to an increase in late-reverse transcription
(RT) products and 2LTR circles, the latter a marker of LV nuclear
import (Follenzi et al., 2000) (Figures S1P and S1Q). Of note, no
changes in the 2LTR/late-RT ratio were observed upon CsH
treatment (FigureS1R), indicating thatCsH relievesanearly block
to transduction prior to DNA synthesis without affecting nuclear2 Cell Stem Cell 23, 1–13, December 6, 2018import. Concordantly, CsH also enhanced transduction of an in-
tegrase-defective LV (IDLV), as measured by an increase in vec-
tor DNA per cell (Figure 1N). CsA was also able to increase IDLV
transduction when packaged with the CypA-independent A88T
mutant capsid (Busnadiego et al., 2014) (Figure S1S). These re-
sults indicate that both cyclosporines relieve an early block to
LV transduction in human HSPC and identify CsH as the most
effective HSPC transduction enhancer described thus far.
CsH Increases LV Transduction and Gene Editing
Efficiency in SCID-Repopulating HSPCs
To assess CsH-enhanced transduction in a more clinically rele-
vant setting, we transplanted human mPB-CD34+ cells trans-
duced with clinical grade LV expressing the alpha-L-iduronidase
(IDUA) transgene (IDUA-LV), designed to treat patients affected
by type I mucopolysaccharidoses (MPS-I) (Visigalli et al., 2010,
2016), into the xenograft NSG mouse model of human hemato-
poiesis and followed engraftment and transduction efficiency
in vivo (Figure 2A). As a control, cells were transduced twice in
the absence of CsH, as per the current standard protocol. No dif-
ferences in colony-forming capacity were observed between
control and CsH-treated cells. The two-hit transduction protocol
showed a slightly increased colony output, likely reflecting the
higher percentage of progenitor cells due to the longer ex vivo
culture period (Figure S2A). Remarkably, one single LV dose in
the presence of CsH was enough to yield significantly higher
gene marking in vitro (Figures S2B and S2C), as well as in
long-term repopulating HSCand derived progeny in vivo (Figures
2B, S2D, and S2E). This surpassed the reference protocol by
2-fold and achieved an almost 10-fold increase in long-term
genemarking in vivo compared to the single transduction control
group. CsH exposure did not alter the short-term engraftment
capacity of HSPC compared to the two-hit protocol but re-
mained slightly below levels achieved with the single-hit control
(Figures 2C and S2F). This could be related to the enhanced level
of transduction as observed previously (Piras et al., 2017).
Indeed, exposure of mPB-CD34+ cells to CsH alone did not
impact early HSPC engraftment (Figures 2D and S2G). Impor-
tantly, we observed higher long-term engraftment, associated
with shorter ex vivo culture, in the BM and spleens for CsH-
treated transduced cells (Figures 2E and S2H–S2L). CsH also
significantly enhanced LV transduction in bona fide long-term
HSC repopulating secondary recipients without affecting their
engraftment capacity (Figures 2F–2H and S2M–S2P).
As CsH enhanced IDLV transduction in human HSPC, we
tested its effect on the efficiency of IDLV-mediated HSPC gene
editing (Figure 2I). Remarkably, delivery of the donor IDLV in the
presence of CsH increased gene editing efficiency in human
HSPC (Figure 2J) without altering the relative composition of
the hematopoietic subpopulations (Figure S2Q). This increase
wasevenmorepronounced in theprimitiveCD34+CD133+CD90+
fraction (Figure 2J) and significantly higher targeting efficiency
was maintained long-term in vivo, reaching an almost 4-fold
increase in gene editing over controls, without affecting engraft-
ment (Figures 2K–2M, S2R, and S2S). Further molecular analysis
confirmed that CsH specifically increased targeted integration by
homology-directed repair (HDR)with the overall fraction of edited
alleles remaining unchanged (Figure S2T). CsH did not affect



















































































































































































































































































































Figure 1. CsH Is a Potent and Non-toxic Enhancer of Lentiviral Vector Transduction in Hematopoietic Stem Cells
(A) Human cord-blood (CB) cells were transduced with a VSV-g lentiviral (LV) at a multiplicity of infection (MOI) of 1 transducing unit (TU)/293T cell ± 8 mMCsA or
CsH. Percentages of transduced cells and vector copy numbers/human genome (VCN/genome) were assessed at 5 or 14 days post-transduction, respectively
(mean ± SEM; n = 20; one-way ANOVA with Bonferroni’s multiple comparison, *p% 0.05, **p% 0.01, ****p% 0.0001).
(B) Impact of CsA and CsH on apoptosis was assessed in hCB-CD34+ cells 48 hr post-transduction (mean ± SEM; n = 6; Dunn’s adjusted Kruskal-Wallis test; ns,
not significant).
(C) VSV-g pseudotyped LV was titered in parallel in 293T cells or human CB-CD34+ cells ± 8 mM CsH (mean ± SEM; n = 4; one-way ANOVA with Bonferroni’s
multiple comparison; ns, not significant, *p% 0.05).
(D and E) Transduction efficiencies (MOI = 1) in human mobilized peripheral blood (mPB)-CD34+ cells (mean ± SEM, n = 4, Mann-Whitney test, *p% 0.05) (D) or
murine hematopoietic stem and progenitor cells (mHSPC) (mean ± SEM, n = 8, Wilcoxon signed rank test, *p = 0.0078) (E).
(F) Transduction efficiencies (MOI = 1) in the different subpopulations of human mPB-CD34+ cells (mean ± SEM, n = 4, Mann-Whitney test versus each DMSO,
*p% 0.05).
(G and H) The composition (G) and cell-cycle status (H) of human mPB- or CB-CD34+ cells, respectively, were evaluated 48 hr post-transduction.
(I) Impact of CsA andCsH on cell proliferation was assessed in hCB-CD34+ cells 48 hr post-transduction (mean ± SEM; n = 4; Dunn’s adjusted Kruskal-Wallis test,
*p% 0.05).
(J–L) hCB- (J and K) and mPB- (L) derived HSPC were transduced in the presence of different drug combinations with LV at an MOI of 1 or 10 (mean ± SEM; n = 7
for I and J, and n = 4 for K; one-way ANOVA with Bonferroni’s multiple comparison, *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001).
(M) Transduction efficiencies ± 8 mM CsH (MOI = 10) in unstimulated hCB-CD34+ cells (unst. hHSPC) (mean ± SEM, n = 4, Mann-Whitney, *p% 0.05).
(N) hCB-CD34+ cells were transduced with an integrase defective LV (IDLV) vector at MOI = 50 ± 8 mM CsH.
See also Figure S1 and Table S1.
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Figure 2. CsH Increases Gene Transfer and Editing in Long-Term SCID-Repopulating Human HSPCs
(A) Experimental scheme of the different transduction protocols using a clinical-grade LV and human mPB-derived CD34+ cells.
(B) VCN/genome were measured in the bone marrow (BM) at 18 weeks (mean ± SEM; n = 8; one-way ANOVA with Bonferroni’s multiple comparison, **p% 0.01,
****p% 0.0001).
(C and D) Engraftment levels in the peripheral blood of mice from different treatment groups transduced (C) or not (D) with IDUA-LV, respectively (mean ± SEM;
nR 11; Dunn’s adjusted Kruskal-Wallis; ns, not significant, **p% 0.01).
(E) Engraftment levels in the BM at 18 weeks post-transplant (mean ± SEM; nR 11; Dunn’s adjusted Kruskal-Wallis; ns, not significant, *p% 0.05).
(F) Experimental design of the secondary transplantation experiment using a purified PGK-GFP LV and human CB-CD34+ cells.
(G) Engraftment levels in the PB, BM, and SPL of secondary mice 13 weeks after transplantation.
(H) Transduction efficiencies (left: GFP+ cells; right: VCN/human genome) in BM and SPL of mice 13 weeks post-injection (mean ± SEM; n = 7, 8 mice per group,
Mann-Whitney test versus DMSO control, **p% 0.01, ***p% 0.001).
(I) Scheme of the gene editing protocol for human CB-derived CD34+ cells.
(legend continued on next page)
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Figure 3. CsH Counteracts an IFN-Inducible
Block to VSV-G-Mediated Vector Entry
(A) THP-1 cells were pre-stimulated or not with
1,000 IU/mL of human IFNa for 24 hr followed
by transduction with a VSV-g pseudotyped LV
(MOI = 1) +/ 8 mM CsH (mean ± SEM; n = 10;
Mann-Whitney test, ***p% 0.001).
(B) THP-1 cells ± 1 ng/mL of human IFNb were
transduced with VSV-g or amphotropic Molony
murine leukemia virus (MLV) pseudotyped LVs
(mean ± SEM, n = 3, Mann-Whitney test, *p = 0.05).
(C) THP-1 cells were pre-stimulated with human
IFNa and transduced with Ampho-MLV pseudo-
typed RV ± CsH (mean ± SEM, n = 4).
(D) THP-1 ± IFNawere transduced with a BaEV-TR
LV (MOI = 0.5–1) +/ CsH (mean ± SEM, n = 4).
(E) Human CB-derived CD34+ cells ± human IFNa
were transduced with a VSV-g pseudotyped LV
(MOI = 1) +/ 8 mMCsH (mean ± SEM; n = 6;Mann-
Whitney test, *p% 0.05, **p% 0.01).
(F) Human CB-derived CD34+ cells ± IFNa were
transduced with BaEV-TR LV (MOI = 0.5-1) +/
CsH (mean ± SEM, nR 4).
See also Figure S3.
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Together, these observations clearly illustrate the value ofCsHas
an enhancer of LV gene transfer and editing and strongly support
its use in therapeutic HSPC gene engineering.
CyclosporinesCounteract an IFN-Inducible Block to VSV
Glycoprotein-Dependent Lentiviral Vector Entry
TounderstandhowCsHenhancesgene transfer/editing inHSPC,
we considered how CsA improves VSV glycoprotein (VSV-G)
pseudotyped LV transduction of IFNa-stimulated monocytic
THP-1 cells (Bulli et al., 2016). We found that CsH also has this
effect (Figures 3A and S3A). Neither calcineurin-inhibitor FK506
nordepletionofcalcineurin, a known target ofCsA, rescued trans-
duction in thisway (FiguresS3BandS3C). Thebest characterized
CsH target, formyl peptide receptor 1 (FPR1) (de Paulis et al.,
1996; Prevete et al., 2015), is also not involved as IFN continued
to suppress LV transduction in FPR1-depleted THP-1 cells
(Figure S3D).
Similar to the CsH-sensitive transduction block in HSPC (Fig-
ures S1P–S1R), the type I IFN-mediated block in THP-1 is
evident by viral DNA synthesis (Figure S3E). Inhibition by type I(J) Percentage of edited cells at AAVS1 locus measured within the indicated subpopulations 3 days after
*p% 0.05, **p% 0.01).
(K) Human CD45+ cell engraftment in PB at indicated times after transplantation of IL2RG edited CB-CD34+
(L) Percentage of gene editing by homology-directed repair (HDR) measured within human cells in mice from
(M) Percentage of human gene edited cells and editing efficiency measured in the BM of mice 19 weeks po
See also Figure S2 and Table S1.
CeIFN requires de novo protein synthesis
as cyclohexamide (CHX) rescued trans-
duction in IFNb-treated cells (Figure S3F).
HIV-1 capsidmutants known to be altered
for interactions with host cofactors CypA
and CPSF6/Nup153 (Lee et al., 2010; Ma-
treyek et al., 2013; Schaller et al., 2011)remained sensitive to IFN (Figure S3G). Similar IFN-induced inhi-
bition and CsA-mediated rescue were observed with diverse
VSV-G pseudotyped retroviral vectors (Figure S3H). However,
vectors pseudotyped with the MLV-derived amphotropic enve-
lope glycoprotein remained insensitive to both type I IFN-medi-
ated inhibition and CsH (Figures 3B and 3C), indicating that
restriction and CsH sensitivity is influenced by the viral envelope.
In agreement with an envelope-dependent mechanism, LV
pseudotyped with the modified Baboon endogenous retroviral
envelope glycoprotein (BaEV-TR) (Girard-Gagnepain et al.,
2014) remained insensitive to both type I IFN and CsH in
THP-1 cells (Figure 3D). Importantly, in IFNa-treated HSPC,
CsH also rescued VSV-G pseudotyped LV transduction (Figures
3E and S3I) but not BaEV-TR LV, which remained less sensitive
to IFNa (Figure 3F). Together, these results are consistent with
cyclosporine-mediated rescue of a type I IFN-inducible block
to VSV-G-mediated LV entry in HSPC/THP-1.
CsH Counteracts IFITM3 Antiviral Activity in HSPCs
Members of the family of interferon induced transmembrane
proteins (IFITMs), in particular IFITM3, have broad antiviralediting (mean ± SEM; n = 7, Mann-Whitney test,
cells (n = 5).
(K).
st-transplantation.
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Figure 4. CsH Counteracts IFITM3 Antiviral Activity
(A) THP-1 cells were transduced with an LV co-expressing GFP and IFITM proteins or Luciferase (Luc) as a control (OE-LV) and then re-challenged with a second
reporter LV. Transduction efficiencies are as fold versus mock (mean ± SEM, nR 6, Wilcoxon signed rank test versus mock = 1, **p = 0.0078).
(B) THP-1 cells overexpressing Luc or IFITM3 were transduced with a reporter LV ± 8 mM CsH (mean ± SEM, nR 20, Mann-Whitney test, ****p% 0.0001).
(C) THP-1 cells depleted for IFITM3 (sh-IFITM3) or expressing a non-silencing small hairpin RNA (shRNA) control (sh-ns) were re-transduced ± IFNa pre-treatment
and ± CsH (mean ± SEM, n = 10, Mann-Whitney test versus each control without hIFNa; ns, not significant, **p% 0.01, ***p% 0.001).
(legend continued on next page)
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such as HIV-1, but not MLV (Brass et al., 2009; Perreira et al.,
2013). IFITM3 acts at the level of viral entry into target cells
(Amini-Bavil-Olyaee et al., 2013; Li et al., 2013). To test whether
IFITMs are involved in the effect of CsH, we first overexpressed
the antiviral IFITM 1, 2, or 3 in THP-1 cells, followed by transduc-
tion with a reporter LV to evaluate IFITM impact on transduction
efficiency (Figure S4A). Only overexpression of IFITM3 resulted
in a significant decrease in LV transduction (Figures 4A and
S4B), and importantly, inhibited transduction was fully rescued
by CsH (Figure 4B). Furthermore, depletion or deletion of IFITM3
led to a full rescue of IFNa-induced LV restriction in THP-1
cells and abrogated CsH-mediated enhancement (Figures 4C,
S4C, and S5A–S5F). We specifically overexpressed IFITM3 in
THP-1 cells deleted for the endogenous IFITM2/3 and further
confirmed its role in LV restriction and cyclosporine enhance-
ment (Figure 4D). Similar to CsH-mediated effects, IFITM3-
dependent restriction was independent of interactions of the
LV capsid with host factors including CypA and CPSF6/
Nup153 (Figure S4D). IFITM3 also impaired IDLV transduction
(Figure S4E). As the CsH-mediated increase in LV transduction
is specific to VSV-G-mediated entry, which occurs by particle
endocytosis (Sun et al., 2005), we tested the capacity of IFITM3
to block BaEV-TR or Ampho-pseudotyped vectors that both
fuse at the plasma membrane (Girard-Gagnepain et al., 2014;
Ragheb et al., 1995). Consistent with their endocytosis-inde-
pendent mechanism of entry, neither pseudotype was inhibited
in THP-1 cells expressing IFITM3 (Figures 4E and 4F). On the
other hand, AAV6 remained insensitive to the action of type I
IFN and IFITM3 (Figure S4F), in agreement with its insensitivity
to CsH in HSPC (Figure S2V). Phosphorylation of the tyrosine
residue in position 20 (Y20) of IFITM3 has been shown to be
required for its activity against VSV-G pseudotyped RV (Jia
et al., 2012). Indeed, overexpressed IFITM3 Y20 mutants failed
to restrict VSV-G pseudotyped LV transduction in THP-1 cells
(Figures 4G, 4H, S4G, and S4H) and remained mostly at the
plasma membrane (Figure 4I), potentially explaining the lack of
restriction.
Importantly, overexpression of IFITM3 in HSPC resulted in a
significant decrease in LV transduction (Figure 5A). Conversely,
depletion of IFITM3 resulted in an enhancement of transduction
(Figure 5B). Moreover, CsH-mediated enhancement of trans-
duction was stronger in IFITM3-overexpressing HSPC and was
almost completely lost with IFITM3 depletion (Figure 5C). These
data were confirmed in vivo as LinHSPC isolated from the bone
marrow of Ifitm3/ mice (Lange et al., 2008) were more permis-
sive to LV transduction and were largely insensitive to CsH-
mediated transduction enhancement as compared to Lin
HSPC isolated from wild-type counterparts (Figure 5D).(D) THP-1 deleted for IFITM3 were transduced with control Luc or IFITM3 expres
Mann-Whitney test, **p% 0.01).
(E) THP-1 cells expressing exogenous Luc or IFITM3 were transduced with a Ba
(F) THP-1 cells deleted for IFITM3 (KO-IFITM3) or control (KO-empty) were tran
protein levels were evaluated at the time of transduction.
(G and H) THP-1 overexpressing the WT or mutated forms of IFITM3 (mean ± SE
deleted for endogenous IFITM3 overexpressing the Luc control or the Y20F form o
(I) Co-localization (purple areas evidence by white arrows) of IFITM3 protein (in re
was evaluated by immunofluorescence in THP-1 cells deleted for the endogenou
See also Figure S4.Intriguingly, individual human HSPC donors expressed
different levels of IFITM3 protein, which negatively correlated
with LV transduction efficiency (Figure 5E). As expected, CsH
enhanced transduction most effectively in samples with higher
IFITM3 expression (Figure 5F). Finally, we investigated the
impact of CsH on IFITM3 expression in bulk or sorted HSPC or
THP-1 stimulated with type I IFN. Significantly lower IFITM3 pro-
tein, but not mRNA, was detected after CsH treatment in both
cell types (Figures 6A, 6B, and S6A–S6D). Interestingly, the inac-
tive IFITM3 Y20F mutant was insensitive to CsH-induced loss in
THP-1 cells (Figure 6C). Of note, removal of CsH prior to trans-
duction resulted in partial restoration of IFITM3 protein levels
within the 6 hr transduction window. This was prevented by
blocking de novo protein synthesis during vector exposure in
HSPC (Figure S6E). These results are in line with CsH being
most effective when added with the vector (Figure S1J). The
transient effect of CsH on IFITM3 protein levels was confirmed
in THP-1 cells overexpressing IFITM3, where IFITM3 protein
levels were restored within 6 hr of CsH removal (Figure S6F).
Overall, these results illustrate how CsH potently enhances
HSPC gene manipulation efficiencies by overcoming an
IFITM3-mediated block to VSV-G-pseudotyped LV infection.
DISCUSSION
Because of concerns of toxicity related to the immunosuppres-
sive function of CsA, a number of non-immunosuppressive
cyclosporine derivatives have been developed and tested for
several applications (Peel and Scribner, 2013). Nevertheless,
most of these still inhibit the host factor CypA. Here, we have
shown that CypA is an important cofactor for efficient lentiviral
transduction of HSPC. Therefore, we sought a non-immunosup-
pressive cyclosporine that did not inhibit CypA, identifying CsH
as, to our knowledge, the most potent enhancer of HSPC gene
transfer (Heffner et al., 2018; Lewis et al., 2018; Wang et al.,
2014; Zonari et al., 2017; Petrillo et al., 2015). Our side-by-side
comparisons illustrate CsH treatment outperforms even the
standard double-hit protocol. Our findings are of particular rele-
vance in gene therapy settings in which high levels of gene
marking are required but difficult to achieve, such as for hemo-
globinopathies, where the large and complex human b-globin
gene expression cassette limits clinical-scale LV production
(Baldwin et al., 2015). CsH utility may extend to other stem cells
populations (Geis et al., 2017; Noser et al., 2006). Moreover, CsH
helps the IDLV-based editing platforms compete with other non-
integrating methods based on AAV or oligonucleotide-mediated
donor DNA delivery (De Ravin et al., 2017; Dever et al., 2016;
Schiroli et al., 2017; Wang et al., 2015), in particular for patients
harboring pre-existing adaptive immunity against some AAVsing LV and re-challenged with a reporter LV ± 8 mM CsH (mean ± SEM, n = 5,
EV-TR LV ± CsH (mean ± SEM, n = 12).
sduced with an Ampho pseudotyped RV ± CsH (mean ± SEM, n = 4). IFITM3
M, n = 12, Mann-Whitney test versus Luc control, ***p% 0.001) (G) or THP-1
f IFITM3 were re-exposed to a reporter LV ± 8 mMCsH (mean ± SEM, n = 5) (H).
d) with the lysosome associated membrane protein 1 (LAMP1) marker (in blue)
s IFITM3 overexpressing the WT or Y20F form of IFITM3.
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Figure 5. CsH Rescues IFITM3-Dependent Early Impairment of LV Transduction in HSPCs
(A and B) IFITM3 was expressed (A) or depleted (B) in human CB-CD34+ cells (A: mean ± SEM, n = 7, Wilcoxon signed rank test versus mock = 1, *p = 0.0156;
B: mean ± SEM, n = 8, Wilcoxon signed rank test versus mock = 1, *p = 0.0313).
(C) IFITM3 protein levels were evaluated by western blot 3–5 days post overexpression and cells were re-challenged with an LV ± 8 mMCsH (Mann-Whitney test,
*p% 0.05).
(D) WT or Ifitm3 knock-out (Ifitm3/) murine Lin HSPC were transduced with LV at MOI 1 ± CsH (mean ± SEM, n = 3 experiments in duplicate each
from 7 WT/Ifitm3/ mice, Wilcoxon signed rank test versus DMSO = 1, *p = 0.0313; Mann-Whitney test; ns, not significant).
(E) Human CD34+ cells from individual donors were transduced at MOI 1 in duplicate and IFITM3 protein levels were evaluated at the time of transduction byWB,
quantified by densitometry using ImageJ software, normalized on Actin and then log-transformed (x axis). Transduction efficiencies were measured by fluo-
rescence-activated cell sorting (FACS) 5 days post-transduction and reported on y axis (mean ± SEM, n = 31 HSPC donors, Spearman correlation, ***p% 0.001,
r = 0.5671).
(F) Human CD34+ cells from individual donors were transduced at MOI 1 in duplicate ± 8 mMCsH and IFITM3 protein levels were evaluated and quantified at the
time of transduction as above (x axis). Transduction efficiencies are expressed in terms of fold-increase in presence of CsH versus DMSO (y axis) (mean ± SEM,
n = 19 HSPC donors, Spearman correlation, *p% 0.05, r = 0.5405).
See also Figure S5.
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transduced cells (Boutin et al., 2010). Of note, the inability of
CsH to increase AAV6-based donor delivery and gene editing,
together with the unaltered overall DNA repair observed in CsH
exposed HSPC, indicates that CsH improves gene editing spe-
cifically through increasing IDLV donor delivery rather than other
effects on the efficiency of DNA break repair. Interestingly, CsH
seemed to increase targeting efficiencies in particular in the
more primitive HSC, previously shown to be more sensitive8 Cell Stem Cell 23, 1–13, December 6, 2018than committed progenitors to the cytotoxicity of the gene tar-
geting procedure and less proficient at performing HDR (Geno-
vese et al., 2014).
Our work reveals that CsH overcomes IFITM3-mediated anti-
viral restriction in HSPC at steady-state. Concordantly, stem
cells, including HSPC, have recently been shown to be naturally
resistant to RNA viral infections due to intrinsic expression of
subsets of antiviral ISGs including IFITM proteins (Wu et al.,
2018). This further supports the idea that constitutively
AB
C
Figure 6. CsH Degrades IFITM3
(A) IFITM3 protein levels were evaluated in human bulk CB-CD34+ cells ± IFNa by immunofluorescence and quantified as integrated density with ImageJ software
after an overnight exposure to CsH (mean ± SEM of three independent experiments in duplicate, n = 18 images; Mann-Whitney test, ***p% 0.001, ****p% 0.0001)
or by western blot as above (one representative blot out of two is shown).
(legend continued on next page)
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Editing In Human Hematopoietic Stem Cells, Cell Stem Cell (2018), https://doi.org/10.1016/j.stem.2018.10.008expressed innate immune factors contribute to poor sensitivity of
HSPC to gene transfer and editing. The antiviral role of IFITM
proteins has been extensively described for a wide range of vi-
ruses (Lu et al., 2011; Perreira et al., 2013; Qian et al., 2015),
although the mechanisms of action remain unclear. IFITM sensi-
tivity of HIV-1 strains is determined by the co-receptor usage of
the viral envelope glycoproteins as well as IFITM subcellular
localization within the target cell (Foster et al., 2016). In LV
designed for gene therapy the HIV-1 envelope glycoprotein
has been replaced with the VSV-G envelope glycoprotein. In
agreement with our observations, IFITM proteins have been
recently shown to limit VSV-G pseudotyped lentivirus-based
vector gene transfer to airway epithelia (Hornick et al., 2016).
Interestingly, pseudotyping LV with the BaEV-TR glycoprotein
has been suggested to significantly improve transduction
efficiencies in human CD34+ cells compared to VSV-G pseudo-
typed vectors, including in unstimulated HSPC (Girard-Gagne-
pain et al., 2014), which is potentially explained by their capacity
to bypass IFITM3 restriction. Rapamycin and PGE2 are also
thought to enhance transduction at the level of VSV-G-mediated
viral entry, (Wang et al., 2014; Zonari et al., 2017), therefore the
involvement of IFITM3 in their effect is worth investigating.
Consistent with previous reports suggesting that IFITM3 acts
at the level of endosomal membrane fusion (Chesarino et al.,
2014; Foster et al., 2016; Jia et al., 2012), AAV6-mediated donor
DNA delivery did not benefit fromCsH. This vector does not have
an envelope and therefore does not fuse with endosomal mem-
branes to enter the cytoplasm (Nonnenmacher and Weber,
2012). Interestingly, CsH seems to abrogate IFITM3 by inducing
its degradation in HSPC and THP-1 cells but fails to impact the
non-restrictive Y20F mutant, potentially due to its misplaced
cellular localization mainly at the plasma membrane or because
Y20 phosphorylation has been suggested to prevent its ubiquiti-
nation by NEDD4 E3 ligase (Chesarino et al., 2014, 2015). Effects
of CsH on IFITM3 were transient as protein levels were restored
within 6 hr from CsH removal, likely explaining the requirement
for the drug during LV exposure for maximal effects.
Importantly, we observed a significant negative correlation
between IFITM3 protein levels and HSPC permissivity to LV
transduction between donors. The least permissive donors
expressed the highest IFITM3 levels and benefitted most from
CsH enhancement of transduction. These data suggest that
CsH will also abrogate donor variability during ex vivo gene ther-
apy, a major benefit for the design of better controlled clinical tri-
als and, eventually, standardized medicinal products based on
modification of HSC. Indeed, donor variability remains a signifi-
cant issue for the field as underscored also by the high variability
in gene marking recently observed for b-Thalassemia gene ther-
apy patients (Thompson et al., 2018). Variations in expression
levels of the antiretroviral host factor TRIM5a have also been
suggested to correlate with human CD34+ cell permissiveness
to lentiviral transduction (Evans et al., 2014) although human
TRIM5a inhibition of HIV-1 is demonstrably weak (Keckesova(B) Freshly isolated FACS-sorted CD34+38133+ HSC were transduced ± CsH
(mean ± SEM, n = 10 images; Mann-Whitney test versus DMSO, *p% 0.05).
(C) IFITM3 protein levels, evaluated by immunofluorescence or by WB as above,
form of IFITM3 were then exposed ± CsH (mean ± SEM of three independent ex
See also Figure S6.
10 Cell Stem Cell 23, 1–13, December 6, 2018et al., 2006). It is possible that, differences in TRIM5a levels,
and other ISGs, reflect variable IFITM3 levels rather than direct
TRIM5a effects on transduction.
Overall, we have described how manipulating a single host
factor can have a dramatic impact on gene transfer efficiencies
in HSPC. Our findings are an important step toward the develop-
ment of maximally effective HSPC gene engineering protocols
and uncover hitherto unknown molecular mechanisms of innate
immune defense in human hematopoietic stem cells. We expect
exploitation in innovative cell and gene therapies and in broadly
effective antiviral strategies.
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Antibodies
Anti-human FCR Blocking Miltenyi Biotec Cat# 130-059-901
Purified Rat Anti-Mouse CD16/CD32 BD Biosciences Cat# 553141; RRID:AB_394656
Anti-human CD45 APC-eFluor 780 eBioscience Cat# 47-0459-42; RRID:AB_1944368; clone HI30
Anti-human CD19 PE BD Biosciences Cat# 345789; clone SJ25C1
Anti-human CD33 BV BD Biosciences Cat# 562854; RRID:AB_2737405; clone WM53
Anti-human CD3 APC BD Biosciences Cat# 555335; RRID:AB_398591; clone UCHT1
Anti-human CD13 BV BD Biosciences Cat# 562596; RRID:AB_2737672; clone WM15
Anti-human CD34 PeCy7 BD Biosciences Cat# 348811; clone 8G12
Anti-human CD34 VB Miltenyi Biotec Cat# 130-095-393; RRID:AB_10827793
Anti human CD38 perCP/Cy5.5 BioLegend Cat# 356614; RRID:AB_2562183; clone HB-7
Anti-human CD38 PeVio770 Miltenyi Biotec Cat# 130-099-151; RRID:AB_2660384
Anti-human CD90 APC BD Biosciences Cat# 559869; RRID:AB_398677; clone 5E10
Anti-human CD133/2 PE Miltenyi Biotec Cat# 130-090-853; RRID:AB_244346; clone 293C3
Anti-human CD45RA PE Miltenyi Biotec Cat# 130-092-248; RRID:AB_615094
Anti-human CD45RA FITC BD Biosciences Cat# 335039; clone HI100
Mouse IgG1 isotype control BD PharMingen Cat# 51-35405X; clone MOPC-21
Mouse polyclonal anti-CypA Santa-Cruz Biotechnology Cat# sc-134310; RRID:AB_2169131
Mouse monoclonal anti-CypB Santa-Cruz Biotechnology Cat# sc-130626; RRID:AB_2169421
Rabbit polyclonal anti-IFITM3 Proteintech Cat# 11714-1-AP; RRID:AB_2295684
Rabbit polyclonal anti-IFITM2 Proteintech Cat# 12769-1-AP; RRID:AB_2122089
Mouse monoclonal anti-IFITM1 Proteintech Cat# 60074-1-Ig; RRID:AB_2233405
Mouse monoclonal anti-b-Actin Sigma-Aldrich Cat# A2228; RRID:AB_476697; clone AC-74
Mouse monoclonal anti-LAMP1 Abcam Cat# ab25630; RRID:AB_470708
Rabbit IgG HRP Linked Whole Ab GE Healthcare Cat# NA934; RRID:AB_772206
Mouse IgG, HRP-Linked Whole Ab GE Healthcare Cat# NA931; RRID:AB_772210
Donkey anti-Rabbit IgG, AlexaFluor 488 Thermo Fisher Scientific Cat# A-21206; RRID:AB_141708
Donkey anti-Rabbit IgG, AlexaFluor 555 Thermo Fisher Scientific Cat# A-31572; RRID:AB_162543
Donkey anti-Rabbit IgG, AlexaFluor 647 Thermo Fisher Scientific Cat# A-31573; RRID:AB_2536183
Biological Samples
Umbilical cord blood Ospedale San Raffaele (TIGET01/09) N/A
Peripheral blood Ospedale San Raffaele (TIGET01/09) N/A
Chemicals, Peptides, and Recombinant Proteins
Cyclosporine A Sigma-Aldrich Cat# C1832-5MG
Cyclosporine H Sigma-Aldrich Cat# SML1575-5MG
Rapamycin Sigma-Aldrich Cat# R8781
FK-506 Sigma-Aldrich Cat# 109581-93-3
Cyclohexamide Sigma-Aldrich Cat# 66-81-9
Prostaglandin E2 Cayman Cat# 14750
Human IFNa pbl assay science Cat# 11105-1
Puromycin Sigma-Aldrich Cat# P8833-25MG
DAPI (40,6-diamidino-2-phenylindole) Roche Cat# 10236276001
Hoechst 33342 Invitrogen Cat# H3570
StemSpan SFEM VODEN Cat# 09650
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GMP Serum-free Stem Cell Growth Cellgenix Cat# 20802-0500
Recombinant human stem cell factor Peprotech Cat# 300-07
Recombinant human thrombopoietin Peprotech Cat# 300-18
Recombinant human Flt3 ligand Peprotech Cat# 300-19
Recombinant human IL6 Peprotech Cat# 200-06
Recombinant human IL3 Peprotech Cat# 200-03
StemRegenin 1 (SR1) BioVision Cat# 1967
UM171 STEMCell Technologies Cat# 72912
3TC Sigma-Aldrich Cat# 134678-17-4
RetroNectin (r-Fibronectin CH-296) Takara Bio Cat# T100A
Bolt 4%–12% Bis-Tris Plus Gels Thermo Fisher Scientific Cat# NW04120BOX
20X Bolt MES SDS Running Buffer Invitrogen Cat# B0002
10X Bolt Sample Reducing Agent Thermo Fisher Scientific Cat# B0009
4X Bolt LDS Sample Buffer Thermo Fisher Scientific Cat# B0007
CD34 MicroBead Kit, human Miltenyi Biotec Cat# 130-046-702
Lineage cell depletion kit Miltenyi Biotec Cat# 130-090-858
CytofixFixation Buffer BD Biosciences Cat# 554655
Permeabilizing Solution 2 BD Biosciences Cat# 347692
CD4+ T Cell Isolation Kit, human Miltenyi Biotec Cat# 130-096-533
Pan Monocyte Isolation Kit, human Miltenyi Biotec Cat# 130-096-537
Critical Commercial Assays
Annexin V Apoptosis Detection Kit I BioLegend Cat# 640918; RRID:AB_1279044
Cell Proliferation Dye eFluor 670 Thermo Fisher Scientific Cat# 65-0840-85
PE Mouse Anti-Ki-67 Set BD Biosciences Cat# 556027; RRID:AB_2266296
ReliaPrep RNA Cell Miniprep System Promega Cat# Z6011
QIAamp DNA Micro Kit QIAGEN Cat# 56304
RNAeasy micro QIAGEN Cat# 74004
RNAeasy Plus micro QIAGEN Cat# 74034
SuperScript Vilo kit Invitrogen Cat# 11754250
P3 Primary Cell 4D-Nucleofector X Kit Lonza Cat# V4XP-3032
T7 Endonuclease I New England Biolabs Cat# M0302L
LV GFP gene (Mr03989638_mr) Thermo Fisher Scientific Cat# 4331182
Human PPIA gene (Hs99999904_m1) Thermo Fisher Scientific Cat# 4331182
Human PPIB gene (Hs00168719_m1) Thermo Fisher Scientific Cat# 4331182
Human IRF7 gene (Hs01014809_g1) Thermo Fisher Scientific Cat# 4331182
Human ISG15 gene (Hs01921425_s1) Thermo Fisher Scientific Cat# 4331182
Human IFITM1 gene (Hs00705137_s1) Thermo Fisher Scientific Cat# 4331182
Human IFITM2 gene (Hs00829485_sH) Thermo Fisher Scientific Cat# 4331182
Human IFITM3 gene (Hs03057129_s1) Thermo Fisher Scientific Cat# 4331182
Human HPRT1 gene (Hs01003267_m1) Thermo Fisher Scientific Cat# 4331182
Experimental Models: Cell Lines
293T cells (HEK293T) ATCC Cat# CRL-11268; RRID:CVCL_1926
THP-1 ATCC Cat# TIB-202; RRID:CVCL_0006
CB-CD34 Lonza Cat# 2C-101
BM-CD34 Lonza Cat# 2M-101C
mPB-CD34 All Cells Cat# mPB015F/mPB016F
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Jackson laboratory (IACUC 784
and 749)
Cat# ARC:NSG, RRID:IMSR_ARC:NSG
Ifitm3/ mice Wellcome Trust Sanger Institute;
Lange et al., 2008
N/A
Oligonucleotides
See Table S1 This paper N/A
Recombinant DNA
pCCLsin.cPPT.hPGK.eGFP.Wpre transfer Petrillo et al., 2015 N/A
pMDLg/Prre packaging Petrillo et al., 2015 N/A
pCMV-Rev Petrillo et al., 2015 N/A
pMD2.VSV-G Petrillo et al., 2015 N/A
pMD.Lg/pRRE.D64VInt Petrillo et al., 2015 N/A
pMDLg/pRRE-N74D GenScript Inc N/A
pMDLg/pRRE-P90A GenScript Inc N/A
BaEV-TR Girard-Gagnepain et al., 2014 N/A
RVrkat43.2MLV GFP Montini et al., 2006 N/A
pCM-gag-pol Montini et al., 2006 N/A
AmphoRV Ragheb et al., 1995 N/A
SIVmac-GFP Mangeot et al., 2002 N/A
SIV3+ Mangeot et al., 2002 N/A
pSVRDNBDM Griffin et al., 2001 N/A
pSVRDNBGFPDH Griffin et al., 2001 N/A
pONY3 Mitrophanous et al., 1999 N/A
pONY8 Mitrophanous et al., 1999 N/A
FP93 Poeschla et al., 1998 N/A
pGINSIN Poeschla et al., 1998 N/A
plko shRNA CypA Open Biosystems TRCN0000049232
plko shRNA IFITM3 Sigma-Aldrich TCRN0000118022
Software and Algorithms
FACSDIVA software BD Biosciences N/A
ImageJ NIH https://imagej.nih.gov/ij/
GraphPad Prism GraphPad Software https://www.graphpad.com/scientific-software/
prism/
FCS Express Flow De Novo Software https://www.denovosoftware.com/site/
DownloadResearch.shtml
Vector NTI Invitrogen N/A
Image Lab Biorad N/A
QuantaSoft Biorad N/A
QuantStudio Real-Time PCR software Applied Biosystems N/A
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG, RRID:IMSR_ARC:NSG)Mus musculus were purchased from Jackson laboratory. All animal
procedures were performed according to protocols approved by the Animal Care and Use Committee of the Ospedale San Raffaelee3 Cell Stem Cell 23, 1–13.e1–e9, December 6, 2018
Please cite this article in press as: Petrillo et al., Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene
Editing In Human Hematopoietic Stem Cells, Cell Stem Cell (2018), https://doi.org/10.1016/j.stem.2018.10.008(IACUC 784 and 749) and communicated to theMinistry of Health and local authorities according to the Italian law. Female 8-10week
old mice were used in all studies to allow better engraftment of human HSPC cells upon tail vein transplantation (Notta et al., 2010).
Mice were observed carefully by laboratory staff and veterinarian personnel for health and activity. Animals weremonitored to ensure
that food and fluid intakemeets their nutritional needs.Micewere housed in cageswithmicroisolator tops on ventilated or static racks
in a specific pathogen-free facility. All caging materials and bedding are autoclaved. All mice were randomized into different HSC
transplantation groups. On the basis of a standard backward sample size calculation, we transplanted at least three to ten mice
per condition and performed at least two independent experiments to obtain a sufficient number of mice to perform statistical anal-
ysis. Human cell engraftment was blindly assessed by serial bleeding or bone marrow as well as spleen analysis at sacrifice. At the
end of the experiments mice were euthanized by CO2 and organs were harvested and analyzed as reported in the Method Details
section.
Cells
Primary cells were isolated from umbilical cord blood or from mononuclear cells collected upon informed consent from healthy
volunteers according to the Institutional Ethical Committee approved protocol (TIGET01/09). Otherwise, cord blood (CB), bone
marrow (BM) or G-CSF mobilized peripheral blood (mPB) CD34+ cells were directly purchased from Lonza or Hemacare. For the
majority of the experiments HSPC from male and female donors were pooled together to have sufficient number of cells for each
experiment. Regarding the correlation study between LV transduction and IFITM3 protein levels we collected HSPC from the
cord blood of single donors without indications regarding the sex.
Total bone marrow from n = 7 background-matched 8-10 week old wild-type and Ifitm3/mice (Wellcome Trust Sanger Institute)
(Lange et al., 2008) were collected and murine Lin cells were isolated as described in Method Details.
METHOD DETAILS
Vectors
Third generation LV stocks were prepared, concentrated and titered as previously described (Dull et al., 1998; Follenzi et al., 2000).
Briefly, self-inactivating (SIN) LV vectors were produced using the transfer vector pCCLsin.cPPT.hPGK.eGFP.Wpre, the packaging
plasmid pMDLg/pRRE, Rev-expressing pCMV-Rev and the VSV-G envelop-encoding pMD2.VSV-G plasmids. IDLV was produced
as previously described (Lombardo et al., 2007) substituting the packaging plasmid pMDLg/pRRE with pMD.Lg/pRRE.D64VInt. For
SINLV capsid mutants, vectors were produced as described above, except that the wild-type pMDLg/pRRE was replaced with a
packaging plasmid harboring a specific point-mutation in the p24 coding region as follows: pMDLg/pRRE-N74D; pMDLg/pRRE-
P90A. All modified packaging plasmidswere purchased fromGenScript Inc. For pseudotyping LVswith themutant baboon retrovirus
envelope, pMD2.VSV-G was replaced by the BaEV-TR during vector production as previously described (Girard-Gagnepain et al.,
2014). Vpx-containing lentiviral vector stocks were produced as previously described (Bobadilla et al., 2013). The SIN-RV was
produced as previously described (Montini et al., 2006) using as transfer vector RVrkat43.2MLV GFP, the packaging plasmid
pCM-gag-pol and the VSV-G envelop-encoding pMD2.VSV-G plasmid or pseudotyped with the amphotropic envelope glycoprotein
(AmphoRV). Simian immunodeficiency virus macaque- (SIVmac) based vectors were produced as previously described (Mangeot
et al., 2002) using an GFP encoding genome SIVmac-GFP, SIVmac packaging plasmid SIV3+ kindly provided by Francois Loic
Cosset and VSV-G pseudotyped. HIV-2 was prepared using HIV-2 packaging construct pSVRDNBDM (also known as HIV-2
pack) and HIV-2 genome encoding GFP pSVRDNBGFPDH (also known as HIV-2 GFP) kindly provided by Andrew Lever (Griffin
et al., 2001). SIV sooty mangabey (SIVsm) GFP encoding vector was made using an SIVmac delta Env construct encoding SIVsm
Gag-Pol and with GFP in place of nef kindly provided by Welkin Johnson. Equine Infectious Anaemia Virus (EIAV) GFP was prepared
using EIAV packaging construct pONY3 and GFP encoding EIAV genome pONY8 kindly provided by Kyriacos Mitrophanous (Mitro-
phanous et al., 1999). Feline immunodeficiency virus (FIF GFP) wasmade using FIVpetaluma packaging construct FP93 and FIV GFP
encoding genome pGINSIN kindly provided by Eric Poeschla (Poeschla et al., 1998). Moloney MLV GFP was produced using MLV
packaging construct CMVintron and MLV genome encoding GFP CNCG kindly provided by Francois Loic Cosset. AAV6 donor tem-
plates for homology-directed repair (HDR) were generated from a construct containing AAV2 inverted terminal repeats, produced by
triple-transfection method and purified by ultracentrifugation on a cesium chloride gradient as previously described (Wang et al.,
2015). Clinical-grade arylsulfatase A (ARSA) and a-l-iduronidase (IDUA) LVs were produced by MolMed (Milan, Italy) using a large
scale validated process as previously reported (Biffi et al., 2013). The bidirectional LVs (Amendola et al., 2013) were used to over-
express the coding sequence (CDS) of candidate human genes under the control of the human phosphoglycerate kinase (PGK) pro-
moter and the eGFP and the minimal cytomegalovirus (mCMV) promoter forming the antisense expression unit. Knock-down (KD)
experiments were performed using plko or vectors encoding shRNA against human CypA (from Open Biosystems,
TRCN0000049232), IFITM3 (from Sigma, TCRN0000118022) or non-silencing (ns) as controls, or pcSIREN vectors expressing
shRNA against CNA, all under the human U6 promoter. The plko ns was designed to express an unrelated shRNA with no predicted
target as control. Knock-out (KO) experiments were performed using LVs co-expressing a mammalian codon-optimized
Cas9 nuclease along with a single guide RNA (sgRNA) (Shalem et al., 2014) against the gene of interest (sgRNA IFITM3:
GGGGGCTGGCCACTGTTGACAGG). As control LV KO-empty with no sgRNA was used.Cell Stem Cell 23, 1–13.e1–e9, December 6, 2018 e4
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Cell lines
The human embryonic kidney 293T cells (HEK293T, RRID:CVCL_1926) were maintained in Iscove’s modified Dulbecco’s medium
(IMDM; Sigma), instead human THP-1 cells (RRID:CVCL_0006) were maintained in Roswell Park Memorial Institute medium
(RPMI; Lonza). Both medium were supplemented with 10% fetal bovine serum (FBS; GIBCO), penicillin (100 IU/ml), streptomycin
(100 mg/ml) and 2% glutamine.
Primary cells
Human CD34+ HSPC, CD4+ and CD14+ monocytes were isolated through positive magnetic bead selection according to
manufacturer’s instructions (Miltenyi) from umbilical cord blood or from mononuclear cells collected upon informed consent from
healthy volunteers according to the Institutional Ethical Committee approved protocol (TIGET01/09). Otherwise, cord blood (CB),
bone marrow (BM) or G-CSF mobilized peripheral blood (mPB) CD34+ cells were directly purchased from Lonza or Hemacare.
CD4+ T cells were activated in RPMI, supplemented with 10% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml), 2% glutamine,
phytohaemagglutanin (PHA) (2 mg/ml, Roche) and IL-2 (300IU/mL, Novartis) for three days and maintained in RPMI, supplemented
with 10% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml), 2% glutamine and IL-2 (300 UI/ml). Monocyte-derived macrophages
(MDM) were differentiated from isolated CD14+ monocytes in DMEM supplemented with 10% FBS, penicillin (100 IU/ml), strepto-
mycin (100 mg/ml), 2% glutamine and 5% human serum AB (Lonza) for seven days. Primary T lymphocytes from healthy donors’
PB mononuclear cells were isolated and activated using magnetic beads conjugated to anti-human CD3 and CD28 antibodies
(Dynabeads human T-activator CD3/CD28; Invitrogen) in IMDM medium (GIBCO-BRL) supplemented with penicillin, streptomycin,
glutamine, 10%FBS, and 5 ng/ml of IL-7 and IL-15 (PeproTech) for 2 days as described (Provasi et al., 2012). BM cells were retrieved
from femurs, tibias, and homer of 8-10 week old wild-type and Ifitm3/ mice (Wellcome Trust Sanger Institute, (Lange et al., 2008).
HSPCs were purified by Lin- selection using the mouse Lineage Cell Depletion Kit (Miltenyi Biotec) according to the manufacturer’s
instructions.
All cells were maintained in a 5% CO2 humidified atmosphere at 37
C.
Compounds
Cyclosporine A, Cyclosporine H, Rapamycin, FK-506 and cyclohexamide (CHX) (all from Sigma-Aldrich) were resuspended and
stored following the manufacturer’ s instructions. They were added to the transduction medium at the indicated concentration
(8 mM for Cyclosporines and 10 mg/ml for Rapa) and washed out with the vector 16-20 hours later. For the FK-506 experiment,
THP1 cells were pre-treated with IFNb (1000U) for 24 h and FK-506 (0.5-1000nM) was added at the time of transduction and left
in the media until cells were harvested 48 h post transduction. CHX (1 mg/ml) was added with IFNb treatment (1000U) 24 h prior
to transduction in THP-1 cells. CHX (10 mg/ml) was added to the medium one hour before CsH wash and re-added during LV trans-
duction for 6 hours in human HSPC. Where described, Prostaglandin E2 (Dinoprostone from Yonsung) was added at the final con-
centration of 10 mM two hours before LV transduction. Human IFNa pre-stimulation was performed for 24 hours together with human
cytokines cocktail at the indicated concentration.
Transduction
If not otherwise specified, all vectors used in this work are vesicular stomatitis virus glycoprotein (VSV-g)-pseudotyped. All cells were
transduced at the indicated multiplicity of infection (MOI) as calculated by titration of vector stocks on 293T cells and expressed as
transducing units (TU)/293T cell. For transduction, human CB-derived hematopoietic stem/progenitor cells (HSPC) were cultured in
serum-free StemSpan medium (StemCell Technologies) supplemented with penicillin (100 IU/ml), streptomycin (100 mg/ml),
100 ng/ml recombinant human stem cell factor (rhSCF), 20 ng/ml recombinant human thrombopoietin (rhTPO), 100 ng/ml recombi-
nant human Flt3 ligand (rhFlt3), and 20 ng/ml recombinant human IL6 (rhIL6) (all from Peprotech) 16 to 24 hours prior to transduction.
HSPC were then transduced at a concentration of 1 3 106 cells per milliliter with a given vector for 16 hours at the indicated multi-
plicity of infection (MOI), expressed as transducing units (TU)/293T cell, in the same medium. For CHX experiments in HSPC, after
24 hours of prestimulation cells were exposed or not to CsH for 16 hours and then transduced for 6 hours in different conditions:
vector alone called ‘‘Reference protocol’’; exposed to the vector after cell wash in absence ‘‘Wash protocol’’ or in presence ‘‘CHX
protocol’’ of CHX. Bone marrow and G-CSF mobilized peripheral blood CD34+ cells were placed in culture on retronectin-coated
non tissue culture-treated wells (T100A Takara) in CellGro medium (Cell Genix) containing a cocktail of cytokines: 60 ng/ml IL-3,
100 ng/ml TPO, 300 ng/ml SCF, and 300 ng/ml FLT-3L (all from Cell Peprotech). Cells were then transduced with the indicated
dose of vectors for 14-15 hours in the same cytokine-containing medium. After transduction with a single hit reporter LV cells
were washed and maintained in serum-free medium supplemented with cytokines as above until the reading of the percentage
of positive cells by FACS, after which they were maintained in IMDM supplemented with 10% FBS, 25 ng/ml rhSCF, 5 ng/ml
rhIL6-3, 25 ng/ml rhFlt3 and 5 ng/ml rhTPO for another seven days before analysis of vector copy numbers. In the protocol that
foresees two rounds of transduction, selected for clinical application, cells were washed for 10 hours in CellGro SCGM medium
supplemented with cytokines and underwent a second hit of transduction in the same conditions as the first, as reported previously
(Biffi et al., 2013). At the end of transduction, cells were counted and collected for clonogenic assays, flow cytometry, and in vivo
studies. Remaining cells were plated in IMDM 10% fetal bovine serum (FBS) with cytokines (IL-3, 60 ng/ml; IL-6, 60 ng/ml; SCF,
300 ng/ml) and cultured for a total of 14 days. Thereafter, cells were collected for molecular and biochemical studies. Unstimulated
HSPC were transduced freshly isolated in StemSpan medium supplemented with penicillin (100 IU/ml), streptomycin (100 mg/ml) fore5 Cell Stem Cell 23, 1–13.e1–e9, December 6, 2018
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to avoid subsequent transduction due to cytokines stimulation.
Murine Lin- HSPC were cultured in serum-free StemSpan medium (StemCell Technologies) containing penicillin, streptomycin,
glutamine and a combination of mouse cytokines (20 ng/ml IL-3, 100 ng/ml SCF, 100 ng/ml Flt-3L, 50 ng/ml TPO all from Peprotech),
at a concentration of 106 cells/ml. After three hours of pre-stimulation, cells were transduced with an LV for 16-20 hours in the same
medium. Cells were then washed and maintained in serum-free medium supplemented with cytokines as above until the reading of
the percentage of positive cells by FACS, after which they were diluted in IMDM supplemented with 10% FBS.
MDM were transduced 7 days after differentiation. T lymphocytes were transduced at a concentration of 106 cells/ml, after
2-3 days of stimulation. The cells were exposed to the vector for 16-20 hours.
Gene editing of human cells
LV donor templates for HDR were generated using HIV-derived, third-generation self-inactivating transfer constructs. IDLV stocks
were prepared and titered as previously described (Lombardo et al., 2007). AAV6 donor templates for HDR were generated from
a construct containing AAV2 inverted terminal repeats, produced by triple-transfection method and purified by ultracentrifugation
on a cesium chloride gradient as previously described (Wang et al., 2015). For gene editing experiments in human HSPC,
106 CD34+ cells/ml were stimulated in serum-free StemSpan medium (StemCell Technologies) supplemented with penicillin, strep-
tomycin, glutamine, 1 mM SR-1 (Biovision), 50 mMUM171 (STEMCell Technologies), 10 mM PGE2 added only at the beginning of the
culture (Cayman), and human early-acting cytokines (SCF 100 ng/ml, Flt3-L 100 ng/ml, TPO 20 ng/ml, and IL-6 20 ng/ml; all
purchased from Peprotech) (Schiroli et al., 2017). Transduction with IDLV was performed at MOI 100, in presence or not of CsH, after
2 days of prestimulation. CD34+ cells were transduced with AAV6 at 10^4 vg/cell 15’ after electroporation. IDLV or AAV6 donor
templates with homologies for AAVS1 locus (encoding for a PGK.GFP reporter cassette; (Genovese et al., 2014) or targeting the
intron 1 of IL2RG (encoding for IL2RG corrective cDNA; (Schiroli et al., 2017) were utilized as indicated. After 24 hours from IDLV
transduction, cells were washed with PBS and electroporated (P3 Primary Cell 4D-Nucleofector X Kit, program EO-100; Lonza)
with 1.25 mM of ribonucleoproteins (RNP). RNPs were assembled by incubating at 1:1.5 molar ratio s.p.Cas9 protein (Integrated
DNA Technologies) with synthetic cr:tracrRNA (Integrated DNA Technologies) for 10’ at 25C. Electroporation enhancer (Integrated
DNA Technologies) was added prior to electroporation according to manufacturer’s instructions. Genomic sequences recognized
by the gRNAs are the following: TCACCAATCCTGTCCCTAGtgg for AAVS1 locus and ACTGGCCATTACAATCATGTggg for
intron 1 IL2RG.Gene editing efficiency wasmeasured from cultured cells in vitro 3 days after electroporation. ForAAVS1 edited cells,
editing by homology-directed repair (HDR) was quantified by flow cytometry measuring the percentage of cells expressing the GFP
marker. For IL2RG edited cells, HDR was quantified by digital droplet PCR analysis designing primers and probe on the junction
between the vector sequence and the targeted locus and on control sequences utilized as normalizer (human TTC5 genes) as pre-
viously described (Schiroli et al., 2017). NHEJ was was measured by mismatch-sensitive endonuclease assay by PCR-based ampli-
fication of the targeted locus followed by digestion with T7 Endonuclease I (NEB) according to the manufacturer’s instructions.
Transplantation of human HSPC in NSG mice
Human mPB-CD34+ cells were pre-stimulated and transduced as described before with IDUA-LV at an MOI of 50 in presence or not
of DMSO/CsH. After transduction 2-5x105 cells were infused into the tail vein of sublethally irradiated 8-10 week-old NSG mice
(radiation dose: 200 cGy for mice weighting 18-25 g and of 220 cGy for mice above 25 g of weight). Transduced and untransduced
cells were also cultured in vitro for 14 days for further analysis. In vitro cultured cells, BM and spleen cells isolated from transplanted
mice at time of sacrifice were then used to quantify the VCN by qPCR. For secondary transplantation experiments 83 104 stimulated
human CB-derived CD34+ cells were injected into the tail vein of primary NSGmice after an over-night transduction with a PGK-GFP
Molmed purified vector (DSP05). Peripheral blood was sampled at indicated times post-transplant and analyzed. At sacrifice, the
cells from the spleen and BM isolated from the primary recipients were analyzed at flow cytometry and the CD34+ cells were purified
from theBM through positivemagnetic bead selection on LD andMScolumns (Miltenyi) according to themanufacturer’s instructions.
Purity was verified by FACS prior to pooling by condition and injection into secondary recipients. Between 93 105 and 13 106 CD34+
cells isolated from the primary hosts were injected into the tail vein of sublethally irradiated secondary NSG mice (8–10 weeks old).
Peripheral blood was sampled at indicated times post-transplant. 13 weeks post-transplantation, all mice were sacrificed by CO2 to
analyze the BM and the spleen of secondary mice as described above (Piras et al., 2017). For transplantation of gene edited cells,
3x105 CD34+ cells treated for editing at day 5 of culture were injected intravenously into NSG mice after sub-lethal irradiation
(180-200 cGy). Human CD45+ cell engraftment and the presence of gene-edited cells were monitored by serial collection of blood
from the mouse tail and, at the end of the experiment (19 weeks after transplantation), BM was harvested and analyzed.
Colony-forming cell assay
Colony-forming cell assays were performed by plating 8x102 human HSPC transduced in presence of the different compounds in a
methylcellulose-based medium (Methocult GF4434; Stem Cell Technologies). Fifteen days later colonies were scored by light micro-
scopy for colony numbers and morphology as erythroid or myeloid. Moreover, they were collected as a pool and as a single colony,
and lysed for molecular analysis to evaluate transduction efficiencies with clinical grade LV.Cell Stem Cell 23, 1–13.e1–e9, December 6, 2018 e6
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All cytometric analyses were performed using the FACS Canto III instrument and LSRFortessa instruments (BD Biosciences) and
analyzed with the FACS Express software (DeNovo Software). Sorting procedures were performed on aMoFlo XDP sorter (Beckman
Coulter).
FACS sorting
Fresh human cord blood-derived CD34+ cells were FACS-sorted according to CD133 and CD38 expression as shown in Figure 6C.
The sorted subpopulations were exposed or not to CsH for 16 hours and then analyzed by IF for IFITM3 protein expression.
Transduced cells
GFP or BFP expression in transduced cells was measured 5-7 days post-transduction and expressed as transduction level (%).
Adherent MDM were detached by scraping in 5mM PBS-EDTA, washed and resuspended in PBS containing 2% fetal bovine serum
(FBS). Cells grown in suspension were washed and resuspended in PBS containing 2% FBS. To measure HSPC subpopulation
composition cells were harvested 16 or 72 hours post-TD, incubated with anti-human receptor blocking antibodies for 15 min
at 4C and then stained for 20 min at 4C with anti-human CD34 (RRID:AB_10827793), CD38 (RRID:AB_2562183), CD45RA
(RRID:AB_615094), CD90 (RRID:AB_398677) or with anti-human CD34, CD133 (RRID:AB_244346), CD90 antibodies (for antibodies
see Key Resources Table). To exclude dead cells from the analysis, 10 ng/ml 7-aminoactinomycin D (7-AAD) was added.
Peripheral blood from mice
For each mouse, 250 mL of peripheral blood were added to 15 mL of PBS containing 45 mg/mL EDTA. For immunostaining a known
volume of whole blood (100 ml) was first incubated with anti-human FcR Blocking Reagent and anti-mouse FcgIII/II receptor (Cd16/
Cd32) blocking antibodies for 15 min at 4C and then incubated in the presence of anti-human CD45 (RRID:AB_1944368), CD19,
CD13, CD3 (RRID:AB_398591) (for antibodies see Key Resources Table) for 20 min at 4C. Erythrocytes were removed by lyses
with the TQ-Prep workstation (Beckman-Coulter) in the presence of an equal volume of FBS (100 ml) to protect white blood cells.
Bone marrow
BM cells were obtained by flushing the femurs in PBS 2% FBS solution. Cells (1x106 cells) were washed, resuspended in 100 mL of
PBS containing 2% FBS, and incubated with anti-human receptor (Cd16/Cd32) blocking antibodies for 15 min at 4C. Staining was
then performed with anti-human CD45, CD19, CD33 (for antibodies see Key Resources Table) for 20 min at 4C. Cells were washed
and finally resuspended in PBS containing 2% FBS.
Spleen
Spleens were first smashed and the resulting cell suspension was passed through 40 mm nylon filter and washed in cold phosphate
buffered saline (PBS) containing 2mMEDTA and 0.5% bovine serum albumine (BSA). Cells were incubated with anti-human receptor
(Cd16/Cd32) blocking antibodies for 15min at 4Cand then stainedwith anti-humanCD45, CD19, CD13, CD3 (for antibodies see Key
Resources Table) for 20 min at 4C. Cells were finally washed and resuspended in PBS containing 2% FBS.
Ki67-Hoechst and Annexin V flow cytometry
Cells were washed and fixed using BD Cytofix buffer (Cat. #554655), washed and permeabilized with BD Perm 2 (Cat. # 347692),
washed and stained with PE-conjugated Ki67 antibody (BD, RRID:AB_2266296) and finally resuspended in BD Cytofix buffer with
Hoechst at 1 mg/mL. The cells were then analyzed on a BD LSRII machine with UV laser. The apoptosis assays were performed
with the Annexin V Apoptosis Detection Kit I (BD Pharmigen, RRID:AB_1279044) according to the manufacturer’s instructions
and 48 hours after transduction.
Cell proliferation assay
Cells were stained with Cell Proliferation Dye eFluor 670 (Affimetrix, eBioscience) after 24 hours of cytokines pre-stimulation and
before cell transduction. This fluorescent dye binds to any cellular protein containing primary amines, and as cells divide, the dye is
distributed equally between daughter cells that can be measured as successive halving of the fluorescence intensity of the dye. At
different time points after TD, cells were harvested and analyzed at flow cytometry. Cell Proliferation Dye eFluor 670 has a peak
excitation of 647 nm and can be excited by the red (633 nm) laser line. It has a peak emission of 670 nm and can be detected
with a 660/20 band pass filter (equivanet to APC, Alexa Fluor 647, or eFluor 660).
RNA extraction, qPCR and gene expression analysis
RNA extraction from cells was performed using the RNeasy micro Kit or RNeasy Plus micro Kit (QIAGEN) or ReliaPrep RNA Cell Mini-
prep System (Promega). Briefly, cells were lysed in Buffer RLT plus, supplemented with beta-mercaptoethanol. RNA was then ex-
tracted according to manufacturer’s instructions. The extracted mRNAs were reverse transcribed (RT) using the SuperScript Vilo
kit (11754250; Invitrogen). RT-qPCR analyseswere performed using TaqMan probes fromApplied Biosystems to detect endogenous
mRNA levels. Otherwise, we designed specific primers to quantify the overexpression of the coding sequence of human IFITM2 and
IFITM3 genes (see below). Q-PCR was run for 40 cycles using the Viia 7 instrument while the Viia 7 software was then used to extract
the raw data (Ct). To determine gene expression, the difference (DCt) between the threshold cycle (Ct) of each gene and that of the
reference gene was calculated by applying an equal threshold. Relative quantification values were calculated as the fold-change
expression of the gene of interest over its expression in the reference sample, by the formula 2–DDCt. The expression was normalized
using the housekeeping gene HPRT1. Human Taqman probes from Applied Biosystems were used and reported in Key
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CB-derived CD34+ cells were transduced at an MOI of 100, in presence or absence of CsA or CsH. To analyze viral replication
intermediates, transduced cells were washed and resuspended in Monini lysis buffer (0.1% polyoxyethylene 10 lauryl ether (Sigma),
0.1mg/mL proteinase K (Promega) (25 ml/ 1X105 cells), incubated at 65C for 2 h and heat inactivated at 94C for 15min (Monini et al.,
1999). Lysis of the cells to retrieve Late-RT and 2-LTR intermediates was performed at 6 or 24 hours post-transduction respectively.
Late-RT and 2LTR circles were measured by quantitative droplet digital-PCR (dd-PCR) assay with primers described below and
normalized using the human TERT gene.
To measure RT products in transduced THP-1 cells, DNA was harvested at 6 h post-transduction using the QIAGEN DNeasy
Blood and Tissue kit, as per manufacturer’s instructions. qPCR was performed using 2x TaqMan Gene Expression Master Mix
(ThermoFisher) and primers and probe for GFP present in the LV genome (LV GFP gene). All the primers used were reported in
Key Resources Table.
Genomic DNA extraction and qPCR
DNA from human CD34+ liquid culture, hematopoietic colony pool samples as well as from murine tissues was extracted using a
Maxwell 16 instrument (Promega) or Blood & Cell Culture DNA micro kit (QIAGEN). DNA from single colonies was lysed in Monini
buffer as previously described (Cassetta et al., 2013). Vector copies per diploid genome (vector copy number, VCN) of the integrated
lentiviral vectors were quantified by quantitative droplet digital-PCR (dd-PCR) using the primers against the primer binding site region
of LVs. VCN quantification of the total lentiviral DNA (integrated and non-integrated) was performed as previously described (Ma´trai
et al., 2011) at three days post-transduction. Copy numbers of the reverse transcribed retroviral vector genome (both integrated and
non-integrated) was performed by quantitative droplet digital-PCR (dd-PCR) discriminating it from plasmid carried over from the
transient transfection using the primers called DU3 sense and PBS antisense and reported in Key Resources Table. Vector copy
numbers and replication intermediates were normalized to genomic DNA content, which was assessed using the human TERT
gene. VCN analysis by ddPCR involved quantification of target and reference loci through the use of duplex target and reference as-
says. In QuantaSoftsoftware copy number was determined by calculating the ratio of the target molecule concentration to the refer-
ence molecule concentration, times the number of copies of reference species in the genome (usually 2). Transduction efficiencies
were evaluated by ddPCR on individual colonies from CFC assay performed on the HSCs transduced with clinical grade LVs and
expressed as percentage (%) of LV+ colonies on total tested as previously reported (Biffi et al., 2013). PCR reaction for ddPCR is:Cycling step Temperature  C Time Number of Cycles
Enzyme Activation 95 5 min 1 ddPCR 200 or 300nM
Denaturation 95 30 s 40
Annealing/Extension 63 1 min 40
Signal Stabilization 4 5 min 1
90 5 min 1
Hold (Optional) 4 Infinite 1Western Blot
Whole cell extracts were prepared as previously described (Kajaste-Rudnitski et al., 2006, 2011). Samples were subjected to SDS-
PAGE using Bolt 4%–12% Bis-Tris Plus Gels (Thermo Fisher Scientific), transferred to PVDF membrane by electroblotting, and
blotted with mouse polyclonal antibody (Ab) raised against CypA (1:500 dilution, RRID:AB_2169131); mouse anti-CypB monoclonal
Ab (1:500 dilution, RRID:AB_2169421); rabbit anti-IFITM3 polyclonal Ab (1:1000 dilution, RRID:AB_2295684); rabbit anti-IFITM2
polyclonal Ab (1:2500, RRID:AB_2122089); mouse anti-IFITM1 monoclonal Ab (1:5000, RRID:AB_2233405). A mouse monoclonal
anti-beta-actin Ab (1;1000 dilution, RRID:AB_476697) was used as a normalizer. After the incubation with primary antibodies,
PVDF membranes were washed three times with tris-buffered saline (TBS) 0.1% tween 20 for 5 minutes and then incubated for
one hour with rabbit or mouse IgG secondary antibodies (1:10000; RRID:AB_772206, RRID:AB_772210).
Immunofluorescence microscopy
3x104 to 5x104 THP-1 or CBCD34+ cells were seeded in Multitest slide glass 10-well 8mm (from MP Biomedicals) precoated with
poly-L-lysine solution (Sigma-Aldrich) for 20 minutes. Cells were fixed with 4% paraformaldehyde (in 1X PBS) for 20 minutes at
room temperature and permeabilized with 0.1% Triton X-100 for 20 minutes at room temperature. For blocking non-specific sites
cells were incubated 30 minutes in PBG (5% BSA, 2% gelatin from cold water fish skin, from Sigma-Aldrich) and then stained
for 2 till 16 hours with rabbit anti-IFITM3 polyclonal antibody (1:200 dilution) and or with a mouse monoclonal anti-LAMP1 (1:100,
RRID:AB_470708). After 3 washes with 1X phosphate-buffered saline, cells were incubated with donkey anti-Rabbit IgG, Alexa Fluor
488 (RRID:AB_141708) or 555 (RRID:AB_162543) or 647 (RRID:AB_2536183) (1:500 dilution fromThermo Fisher Scientific) for 2 hours
at room temperature. Nuclei were stained with DAPI (40,6-diamidino-2-phenylindole) for 10 minutes at room temperature. ImagesCell Stem Cell 23, 1–13.e1–e9, December 6, 2018 e8
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QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were conducted with GraphPad Prism 5.04 version. In all studies, values are expressed as mean ± standard
error of the mean (SEM) and all n numbers represent biological repeats. Statistical analyses were performed by Mann Whitney or
Wilcoxon Signed Rank test between means of two groups and by ANOVA or Dunn’s adjusted Kruskal–Wallis for multiple compari-
sons, as indicated in the Figure legends. For WB quantifications, signal was quantified by densitometry using the ImageJ software
and normalized to actin, then log10 transformed for the purposes of the correlation statistics and graphical representation when
needed. For correlation studies Spearman’s rank correlation coefficient was calculate. Experimental models were randomly as-
signed to treatment groups.
Differences were considered statistically significant at *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ‘‘ns’’ represents non
significance.e9 Cell Stem Cell 23, 1–13.e1–e9, December 6, 2018
